Preparing projects...
Preparing projects...Preparing projects...
Preparing projects...ARC-HIVE
Loading filters and project entries. Please hold on while we fetch the database.
Loading search filters and projects…
Loading search filters and projects…Project Register
Filter the project register by health boards, sponsors, organisations, date range, or project status. Each record contains project details, research timeline, and participating organisations.
Showing 1 to 8 of 8 projects
| Project | Status | Start Date | Health Boards | Sponsors | |
|---|---|---|---|---|---|
Development and Feasibility Testing of Intervention to Reduce Anticholinergic Burden in Older Adults Aged 65 Years and Over Background: Anticholinergic burden (ACB) from medications has been associated with adverse outcomes in older adults. Aim: The aim was to conduct a non-randomized feasibility study of an intervention to reduce the anticholinergic burden in older patients (REGENERATE) to inform a subsequent definitive trial. Methods: The development and evaluation of an ACB reduction intervention was guided by the Medical Research Council framework. Findings from preliminary studies, two systematic reviews, and two qualitative studies informed the design of a mixed-method feasibility study. The study was conducted in one UK primary care site. The clinical pharmacist identified and invited potentially eligible patients, reviewed their medications, and made recommendations to reduce the ACB as needed. Patients completed surveys at baseline and 6 and 12 weeks post-intervention. A purposive sample of patients and healthcare professionals was interviewed. | COMPLETED | 01 Jan 2019 | NHS Grampian | University of Aberdeen | |
Reducing the anticholinergic and sedative load in older patients on polypharmacy by pharmacist-led medication review A randomised controlled single blind trial was conducted in 15 community pharmacies in the Northern Netherlands. 157 community-dwelling patients aged ≥65 years who used ≥5 medicines for ≥3 months, including at least one psycholeptic/psychoanaleptic medication and who had a DBI≥1 were recruited. The intervention was a medication review by the community pharmacist in collaboration with the patient's general practitioner and patient. The primary outcome was the proportion of patients whose DBI decreased by at least 0.5. Secondary outcomes included presence of anticholinergic/sedative side effects, falls, cognitive function, activities of daily living, quality of life, hospital admission and mortality. Data were collected at baseline and 3 months follow-up. | COMPLETED | 01 Dec 2014 | Other | Dutch Pharmacy Society | |
Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden An 8-week, parallel-arm, randomized trial was conducted to evaluate a targeted patient-centered pharmacist–physician team medication therapy management (MTM) intervention to improve anticholinergic medication appropriateness and reduce the use of inappropriate anticholinergic medications in older patients. Participants were randomized to intervention or control group. The intervention group received a medication review and recommendations for discontinuation or replacement of anticholinergic medications. Outcomes included changes in medication appropriateness index (MAI) and anticholinergic drug scale (ADS) scores. | COMPLETED | 01 Oct 2014 | Other | University of Kentucky Center for Clinical and Translational Sciences | |
Evaluation of a pharmacist-led pilot service based on the anticholinergic risk scale This pilot service evaluated medical records of patients aged 60+ with high health care utilization and polypharmacy. Anticholinergic Risk Scale (ARS) scores were calculated, and medication therapy recommendations were sent electronically to primary care physicians for patients with ARS >3. Post-visit outcomes were recorded. The project was conducted at two medical clinics within Dean Health System using a standardized algorithm and decision support tools. | COMPLETED | 01 Jan 2014 | Other | Dean Health System | |
Reduction of anticholinergic burden in older patients admitted to a multidisciplinary geriatric acute care unit The study included patients over 80 years old admitted to an acute geriatric unit. Data on demographics, comorbidities, and medications were collected. Anticholinergic burden was calculated using three scales (ADS, ARS, ACB) at admission and discharge. Pharmacists collaborated in clinical interviews, medication reconciliation, and validation using STOPP/START criteria. The study found significant reductions in anticholinergic burden using ARS and ACB scales. | COMPLETED | 01 Jan 2014 | Other | Not specified | |
Drug Burden Index and Potentially Inappropriate Medications in Community-Dwelling Older People A retrospective analysis of medication reviews was performed for 372 community-dwelling older people (aged ≥65 years) who received an HMR service from the pharmacist. The main outcome measure was the total DBI score at baseline and post-HMR. The data were also examined to determine the extent of potentially inappropriate medication (PIM) use (2003 Beers' criteria), and the number and nature of pharmacists' recommendations. | COMPLETED | 01 Jan 2013 | Other | Not specified | |
A Pilot Randomized Clinical Trial Utilizing the Drug Burden Index to Reduce Exposure to Anticholinergic and Sedative Medications in Older People This was a cluster randomized controlled trial with 3 months of follow-up. Participants were aged ≥70 years living in self-care retirement villages in Sydney. The intervention involved a letter and phone call to GPs using DBI to prompt them to consider cessation or dose reduction of anticholinergic and sedative medications. The primary outcome was to assess the impact of DBI information on prescribing practices. | COMPLETED | 01 Feb 2008 | Other | Geoff and Elaine Penney Ageing Research Unit | |
Cognitive Effects of Reducing Anticholinergic Drug Burden in a Frail Elderly Population: A Randomized Controlled Trial A randomized, controlled, single-blinded trial conducted in 22 nursing homes in Norway. Long-term residents with an ADS score ≥3 were randomly allocated to intervention or control. The intervention involved pharmacist-led multidisciplinary drug reviews to reduce ADS score. Cognitive function was assessed using immediate recall, Mini-Mental State Examination, delayed recall, recognition of words, saliva flow, and serum anticholinergic activity. Participants were retested after 4 and 8 weeks. | COMPLETED | 01 Jan 2008 | Other | South-Eastern Norway Regional Health Authority |
Background: Anticholinergic burden (ACB) from medications has been associated with adverse outcomes in older adults. Aim: The aim was to conduct a non-randomized feasibility study of an intervention to reduce the anticholinergic burden in older patients (REGENERATE) to inform a subsequent definitive trial. Methods: The development and evaluation of an ACB reduction intervention was guided by the Medical Research Council framework. Findings from preliminary studies, two systematic reviews, and two qualitative studies informed the design of a mixed-method feasibility study. The study was conducted in one UK primary care site. The clinical pharmacist identified and invited potentially eligible patients, reviewed their medications, and made recommendations to reduce the ACB as needed. Patients completed surveys at baseline and 6 and 12 weeks post-intervention. A purposive sample of patients and healthcare professionals was interviewed.
A randomised controlled single blind trial was conducted in 15 community pharmacies in the Northern Netherlands. 157 community-dwelling patients aged ≥65 years who used ≥5 medicines for ≥3 months, including at least one psycholeptic/psychoanaleptic medication and who had a DBI≥1 were recruited. The intervention was a medication review by the community pharmacist in collaboration with the patient's general practitioner and patient. The primary outcome was the proportion of patients whose DBI decreased by at least 0.5. Secondary outcomes included presence of anticholinergic/sedative side effects, falls, cognitive function, activities of daily living, quality of life, hospital admission and mortality. Data were collected at baseline and 3 months follow-up.
An 8-week, parallel-arm, randomized trial was conducted to evaluate a targeted patient-centered pharmacist–physician team medication therapy management (MTM) intervention to improve anticholinergic medication appropriateness and reduce the use of inappropriate anticholinergic medications in older patients. Participants were randomized to intervention or control group. The intervention group received a medication review and recommendations for discontinuation or replacement of anticholinergic medications. Outcomes included changes in medication appropriateness index (MAI) and anticholinergic drug scale (ADS) scores.
This pilot service evaluated medical records of patients aged 60+ with high health care utilization and polypharmacy. Anticholinergic Risk Scale (ARS) scores were calculated, and medication therapy recommendations were sent electronically to primary care physicians for patients with ARS >3. Post-visit outcomes were recorded. The project was conducted at two medical clinics within Dean Health System using a standardized algorithm and decision support tools.
The study included patients over 80 years old admitted to an acute geriatric unit. Data on demographics, comorbidities, and medications were collected. Anticholinergic burden was calculated using three scales (ADS, ARS, ACB) at admission and discharge. Pharmacists collaborated in clinical interviews, medication reconciliation, and validation using STOPP/START criteria. The study found significant reductions in anticholinergic burden using ARS and ACB scales.
A retrospective analysis of medication reviews was performed for 372 community-dwelling older people (aged ≥65 years) who received an HMR service from the pharmacist. The main outcome measure was the total DBI score at baseline and post-HMR. The data were also examined to determine the extent of potentially inappropriate medication (PIM) use (2003 Beers' criteria), and the number and nature of pharmacists' recommendations.
This was a cluster randomized controlled trial with 3 months of follow-up. Participants were aged ≥70 years living in self-care retirement villages in Sydney. The intervention involved a letter and phone call to GPs using DBI to prompt them to consider cessation or dose reduction of anticholinergic and sedative medications. The primary outcome was to assess the impact of DBI information on prescribing practices.
A randomized, controlled, single-blinded trial conducted in 22 nursing homes in Norway. Long-term residents with an ADS score ≥3 were randomly allocated to intervention or control. The intervention involved pharmacist-led multidisciplinary drug reviews to reduce ADS score. Cognitive function was assessed using immediate recall, Mini-Mental State Examination, delayed recall, recognition of words, saliva flow, and serum anticholinergic activity. Participants were retested after 4 and 8 weeks.